Allergy Immunotherapy Market Report 2026

The allergy immunotherapy market size has grown rapidly in recent years. It will grow from $3.16 billion in 2025 to $3.55 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to limited awareness about allergy immunotherapy, rising incidence of seasonal allergic rhinitis, dependency on hospital-based treatment channels, adoption of traditional treatment methods, regulatory approvals for immunotherapy products.

The allergy immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to growth in personalized immunotherapy solutions, increasing adoption of online pharmacy channels, expansion of pediatric allergy treatment, rising investment in immunotherapy research, development of combination immunotherapy products. Major trends in the forecast period include increasing adoption of subcutaneous and sublingual immunotherapy, rising prevalence of allergic rhinitis and asthma, expansion of food and venom allergy treatments, growing focus on personalized allergy treatment protocols, enhanced awareness and early diagnosis of allergic conditions.

The rising prevalence of allergic disorders is expected to drive the growth of the allergy immunotherapy market in the coming years. Allergic disorders occur when the immune system overreacts to specific antigens. Immune responses that mistakenly target the body’s own tissues result in autoimmune diseases. Allergy immunotherapy is available for atopic individuals with allergic conditions such as IgE-mediated allergic rhinitis and allergic asthma, which are triggered by inhaled allergens like pollens and house dust mites (HDMs). For instance, in August 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA), a UK-based executive agency, reported that English hospitals recorded over 25,000 admissions for allergies and anaphylaxis in 2022-23, more than double the number seen over the past twenty years. Additionally, in May 2024, the Food Standards Agency, a UK-based government department, published the Patterns and Prevalence of Adult Food Allergy (PAFA) report, indicating that around 6% of adults in the UK - approximately 2.4 million people - are affected by food allergies. Therefore, the increasing prevalence of allergic disorders is supporting the growth of the allergy immunotherapy market.

Major companies in the allergy immunotherapy market are developing innovative technological solutions, such as AI-powered allergy component testing, to maintain their competitive position. AI-powered allergy component testing is a cutting-edge platform based on component-resolved diagnostics (CRD) for identifying various types of allergies. For instance, in May 2023, Metropolis Healthcare Limited, an India-based medical laboratory company, launched an AI-powered allergy component testing platform. This fourth-generation allergy testing technology uses AI to assist clinicians in making informed clinical decisions. It provides detailed insights for selecting and optimizing treatment plans for allergic conditions and can also predict the likely effectiveness of immunotherapy for allergy vaccines.

In January 2024, Inimmune Corporation, a US-based biotechnology company, entered into a strategic collaboration with Intrommune Therapeutics, Inc. to develop next-generation immunotherapy solutions for food allergies. Through this partnership, the companies aim to create a rapid, long-acting oral mucosal allergy immunotherapy for peanut allergy, combining Inimmune’s proprietary rapid desensitization technology with Intrommune’s oral mucosal immunotherapy platform. Intrommune Therapeutics, Inc., a US-based company, specializes in food-allergy immunotherapy solutions designed to achieve allergen desensitization through oral mucosal exposure.

Major companies operating in the allergy immunotherapy market are LETI Pharma, Stallergenes Greer International AG, Allergy Therapeutics plc, ALK-Abelló A/S, HAL Allergy B.V., DBV Technologies, Circassia Pharmaceuticals Inc., Jubilant HollisterStier LLC, Allergopharma GmbH & Co. KG, Biomay AG, Anergis SA, HollisterStier Allergy, Desentum Oy, WOLW Pharma Limited, AllerGenics Inc., Greer Laboratories Inc., Aimmune Therapeutics Inc., Reliant Laboratories Inc., Mylan N.V., Adamis Pharmaceuticals Corporation, Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd.

Europe was the largest region in the allergy immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the allergy immunotherapy market report during the forecast period. The regions covered in the allergy immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allergy immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the allergy immunotherapy market by increasing the cost of imported allergens, immunotherapy kits, and specialized delivery devices. Subcutaneous and sublingual immunotherapy products are most affected, with north america and europe facing higher import costs. This has led to increased treatment expenses and supply chain adjustments. Positively, tariffs have encouraged domestic production of allergens and immunotherapy kits, promoting local innovation and reducing dependency on imports over time.

The allergy immunotherapy market research report is one of a series of new reports that provides allergy immunotherapy market statistics, including allergy immunotherapy industry global market size, regional shares, competitors with a allergy immunotherapy market share, detailed allergy immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the allergy immunotherapy industry. This allergy immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Allergy immunotherapy is a type of treatment aimed at preventing allergic reactions to substances such as house dust mites, grass pollen, and bee venom. This therapy involves administering gradually increasing doses of the allergen or chemical to which the patient is sensitive.

The primary allergy types addressed in allergy immunotherapy include allergic rhinitis, asthma, food allergy, venom allergy, and others. Allergic rhinitis is a condition associated with a set of symptoms affecting the nose. The treatments used include immunotherapy (SCIT), sublingual immunotherapy, and specific immunotherapy (SIT). The main distribution channels consist of hospital pharmacies, retail pharmacies, and online pharmacies.

The allergy immunotherapy market includes revenues earned by entities by providing monoclonal antibodies and immune checkpoint inhibitors therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.